Switch theme
Sign up to access all valuation multiples
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. Its drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.
2000
52
LTM Revenue $6.2M
LTM EBITDA -$18.6M
$15.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alligator Bioscience has a last 12-month revenue (LTM) of $6.2M and a last 12-month EBITDA of -$18.6M.
In the most recent fiscal year, Alligator Bioscience achieved revenue of $6.0M and an EBITDA of -$17.1M.
Alligator Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alligator Bioscience valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.2M | XXX | $6.0M | XXX | XXX | XXX |
| Gross Profit | $6.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$18.6M | XXX | -$17.1M | XXX | XXX | XXX |
| EBITDA Margin | -302% | XXX | -286% | XXX | XXX | XXX |
| EBIT | -$23.6M | XXX | -$19.6M | XXX | XXX | XXX |
| EBIT Margin | -384% | XXX | -328% | XXX | XXX | XXX |
| Net Profit | -$24.1M | XXX | -$24.1M | XXX | XXX | XXX |
| Net Margin | -392% | XXX | -405% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alligator Bioscience's stock price is SEK 4 (or $0).
Alligator Bioscience has current market cap of SEK 134M (or $13.8M), and EV of SEK 147M (or $15.2M).
See Alligator Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.2M | $13.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alligator Bioscience has market cap of $13.8M and EV of $15.2M.
Alligator Bioscience's trades at 2.5x EV/Revenue multiple, and -0.9x EV/EBITDA.
Equity research analysts estimate Alligator Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alligator Bioscience has a P/E ratio of -0.6x.
See valuation multiples for Alligator Bioscience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13.8M | XXX | $13.8M | XXX | XXX | XXX |
| EV (current) | $15.2M | XXX | $15.2M | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | -0.9x | XXX | XXX | XXX |
| EV/EBIT | -0.6x | XXX | -0.8x | XXX | XXX | XXX |
| EV/Gross Profit | 2.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | -0.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlligator Bioscience's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.5M for the same period.
Alligator Bioscience's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alligator Bioscience's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alligator Bioscience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -302% | XXX | -286% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 265% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 428% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alligator Bioscience acquired XXX companies to date.
Last acquisition by Alligator Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Alligator Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alligator Bioscience founded? | Alligator Bioscience was founded in 2000. |
| Where is Alligator Bioscience headquartered? | Alligator Bioscience is headquartered in Sweden. |
| How many employees does Alligator Bioscience have? | As of today, Alligator Bioscience has 52 employees. |
| Who is the CEO of Alligator Bioscience? | Alligator Bioscience's CEO is Mr. Soren Bregenholt. |
| Is Alligator Bioscience publicy listed? | Yes, Alligator Bioscience is a public company listed on STO. |
| What is the stock symbol of Alligator Bioscience? | Alligator Bioscience trades under ATORX ticker. |
| When did Alligator Bioscience go public? | Alligator Bioscience went public in 2016. |
| Who are competitors of Alligator Bioscience? | Similar companies to Alligator Bioscience include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Alligator Bioscience? | Alligator Bioscience's current market cap is $13.8M |
| What is the current revenue of Alligator Bioscience? | Alligator Bioscience's last 12 months revenue is $6.2M. |
| What is the current EV/Revenue multiple of Alligator Bioscience? | Current revenue multiple of Alligator Bioscience is 2.5x. |
| Is Alligator Bioscience profitable? | Yes, Alligator Bioscience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alligator Bioscience? | Alligator Bioscience's last 12 months EBITDA is -$18.6M. |
| What is Alligator Bioscience's EBITDA margin? | Alligator Bioscience's last 12 months EBITDA margin is -302%. |
| What is the current EV/EBITDA multiple of Alligator Bioscience? | Current EBITDA multiple of Alligator Bioscience is -0.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
